Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SCNX
stocks logo

SCNX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Scienture Holdings Inc (SCNX.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Scienture Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SCNX News & Events

Events Timeline

(ET)
2025-11-13
08:14:26
Scienture announces Q3 earnings per share of 19 cents, compared to a loss of $1.34 in the same period last year.
select
2025-11-04 (ET)
2025-11-04
08:28:18
Scienture adds Arbli to national health plan formularies
select
2025-10-23 (ET)
2025-10-23
08:20:49
Scienture Launches Commercial Sales and Begins Fulfilling Initial Arbli Orders
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
12-02Globenewswire
Scienture Holdings to Present at iAccess Alpha Virtual Investment Conference 2025
  • Conference Participation: Scienture Holdings will participate in the iAccess Alpha Virtual Investment Conference from December 9-10, 2025, where management aims to showcase new products to attract investor interest in its market potential.
  • Executive Presentation: President and co-CEO Narasimhan Mani is scheduled to present at 2 PM EST on December 9, followed by one-on-one meetings with investors on December 10, enhancing engagement with potential investors.
  • Live Webcast: The conference will feature a live webcast available on the company's website and a dedicated link, ensuring investors can access the latest company updates in real-time, thereby increasing transparency and investor confidence.
  • Market Positioning: By participating in such investment conferences, Scienture aims to demonstrate its capability in addressing unmet market needs, further solidifying its market position within the pharmaceutical industry.
[object Object]
Preview
9.5
11-13Benzinga
EXCLUSIVE: Scienture Reports Surge in Q3 Revenue Driven by Arbli Sales and Debt Reduction

  • Financial Performance: Scienture Holdings reported a significant increase in net revenue from approximately $65,000 to $590,000 and gross profit from roughly $4,000 to $575,000 in Q3, marking a transformational quarter for the company.

  • Debt Reduction and Cash Position: After Q3, Scienture improved its financial stability by reducing outstanding debt and enhancing its cash position to over $8 million as of November 13, 2025.

  • Product Launches: The company successfully launched Arbli, an oral suspension for hypertension, which has been added to key national payors' formularies, expanding access to over 100 million covered lives in the U.S.

  • Future Plans: Scienture is preparing to launch Rezenopy, an opioid overdose emergency treatment, in Q1 2026, while continuing to evaluate opportunities to expand its product portfolio.

[object Object]
Preview
5.0
11-04Benzinga
EXCLUSIVE: Scienture Broadens Availability of Arbli Losartan Oral Suspension by Adding to Formularies for 100 Million Individuals

  • Arbli's Market Access: Scienture Holdings announced that Arbli (losartan potassium) Oral Suspension has been added to key national payors' formularies, increasing access to over 100 million covered lives in the U.S.

  • Product Overview: Arbli is the first FDA-approved ready-to-use oral suspension of losartan, designed for patients needing an alternative to solid dosage forms, and is indicated for hypertension and related conditions in patients over six years old.

  • Commercial Opportunity: The U.S. losartan market is valued at approximately $256 million annually, with over 71 million prescriptions written each year, presenting a significant opportunity for Scienture.

  • Stock Performance: Following the announcement, SCNX stock experienced a decline of 2.40%, trading at $0.69 during the premarket session.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Scienture Holdings Inc (SCNX) stock price today?

The current price of SCNX is 0.6061 USD — it has decreased -0.33 % in the last trading day.

arrow icon

What is Scienture Holdings Inc (SCNX)'s business?

Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.

arrow icon

What is the price predicton of SCNX Stock?

Wall Street analysts forecast SCNX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SCNX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Scienture Holdings Inc (SCNX)'s revenue for the last quarter?

Scienture Holdings Inc revenue for the last quarter amounts to 590.05K USD, increased 809.71 % YoY.

arrow icon

What is Scienture Holdings Inc (SCNX)'s earnings per share (EPS) for the last quarter?

Scienture Holdings Inc. EPS for the last quarter amounts to -0.19 USD, decreased -85.82 % YoY.

arrow icon

What changes have occurred in the market's expectations for Scienture Holdings Inc (SCNX)'s fundamentals?

The market is revising No Change the revenue expectations for SCNX for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -31.61%.
arrow icon

How many employees does Scienture Holdings Inc (SCNX). have?

Scienture Holdings Inc (SCNX) has 14 emplpoyees as of December 05 2025.

arrow icon

What is Scienture Holdings Inc (SCNX) market cap?

Today SCNX has the market capitalization of 24.63M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free